Takara Bio grants Cellectis SA a commercial license to use RetroNectin®
Kusatsu/Shiga, Japan – March 22, 2016 – Takara Bio Inc. announces that it has entered into a License and Supply Agreement with Cellectis SA. Under the agreement, Takara Bio grants Cellectis a commercial license to use RetroNectin® and Takara Bio also supplies RetroNectin® to Cellectis . Cellectis is the ninth conpany that Takara Bio has granted a RetroNectin® commercial use license.
The patented technologies licensed to Cellectis are based on Takara Bio’s proprietary “RetroNectin® method” which includs a technology enabling highly efficient gene transduction to cells by retroviral vector. With such advantages, RetroNectin® method is now becoming increasingly standard in protocols utilized for “Engineered T-cell Therapy” including TCR and CAR gene therapies which have recently raising higher expectations.
Cellectis, by leveraging its proprietary gene editing technology TALEN®, is advancing clinical development of CAR gene therapy in which healthy donors-derived (allogenic) T lymphocytes are utilized.
Takara Bio is promoting supply of RetroNectin® to clinical development of Engineered T-cell Therapy actively pursued worldwide in recent years, and expects higher sales growth in the future.
This article is translated from press release in Japanese for your convenience.
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.